Navigation Links
Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
Date:11/14/2007

multi-center randomized trial comparing the ClosureFAST treatment to endovenous laser. Patients undergoing laser treatment were 33% more likely to experience pain and 50% more likely to require postoperative pain medication than patients who received the ClosureFast treatment.

"The ClosureFAST device is clearly emerging as the preferred treatment for venous reflux, in part because of reduced patient discomfort after treatment," said Dr. Almeida. "While procedure time and short-term efficacy are comparable between ClosureFAST and laser, we're definitely seeing a superior patient recovery profile with ClosureFAST."

"We are pleased to see the positive interim study results on our ClosureFAST catheter, especially the favorable patient recovery profile compared to laser treatment and the better-than-anticipated one-year efficacy rate," said Brian E. Farley, President and CEO of VNUS. "We believe the final results will support our belief that ClosureFAST is the best choice for the treatment of venous reflux disease for the millions of varicose vein sufferers around the world."

ABOUT VEITH SYMPOSIUM

Now in its fourth decade, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The five-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. VEITHsymposium is sponsored by The Cleveland Clinic, Cleveland, OH.

ABOUT VNUS MEDICAL TECHNOLOGIES, INC.

Founded in 1995 and headquartered in San Jose, California, VNUS Medical Technologies (Nasdaq:

SOURCE VNUS Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
5. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
6. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- Manchester Pharmaceuticals, Inc.(TM) announced today the availability ... October 22, 2009, the US Food and Drug ... patients suffering from gallstones in whom surgery poses ... advanced age. ,, Chenodal prescriptions have started to ... Resources ("Centric"), a specialty pharmacy company. Centric ...
(Date:12/14/2009)... -- Pf enex Inc. announced today ... an affiliate, an exclusive worldwide license to Pf ... technology for the production of specific proteins ... vaccine candidate. ,, Under the terms of the ... $52 million in upfront and milestone payments as well ...
(Date:12/14/2009)... N.J., Dec. 14 Watson Pharmaceuticals, Inc. ... new program encouraging health professionals to help maintain ... are on long-term androgen deprivation therapy (ADT). ... palliative treatment for prostate cancer that, while highly ... bone loss and increase a man,s risk for ...
Breaking Medicine Technology:Manchester Announces Availability of Chenodal(TM) 2Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 2Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 3Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 4Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 5Rodent smoke screen 11032 1Rodent smoke screen 11032 2Disability Firm Advocates for Valley 26apos 3Bs Needy Families 62842 1Disability Firm Advocates for Valley 26apos 3Bs Needy Families 62842 2Disability Firm Advocates for Valley 26apos 3Bs Needy Families 62842 3Music of Mozart Soothes the Preemie Baby 62837 1Music of Mozart Soothes the Preemie Baby 62837 2Music of Mozart Soothes the Preemie Baby 62837 3
... EXTON, Pa., April 16 ViroPharma Incorporated,(Nasdaq: ... Pharmaceuticals, a,division of Wyeth (NYSE: WYE ), ... the previously announced safety issue that emerged in ... C., "Clearly, this is a disappointing outcome ...
... April 16 Repligen Corporation,(Nasdaq: RGEN ) ... Administration,(FDA) has granted Fast Track designation to the ... the assessment of pancreatic,duct structures by magnetic resonance ... facilitate the development and expedite the review of,drugs ...
Other Medicine Technology:ViroPharma Announces Discontinuation of HCV-796 Development 2Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging 2Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging 3Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging 4
(Date:12/14/2009)... physical, mental functioning , , , MONDAY, Dec. 14 (HealthDay ... tend to live longer than those who look older ... finding came from research that involved 1,826 Danish twins, ... cognitive tests and then had their faces photographed. Three ... the age they perceived the participants to be. Twins ...
(Date:12/14/2009)... Foundation’s Nothing But Nets tipped off a promotion--Send a Net. Save ... nets to refugees in 11 African countries. The effort is part ... 31, 2010. , ... New York, NY ... and the United Nations Foundation’s Nothing But Nets tipped off a ...
(Date:12/14/2009)... Dec. 14 Concetta F. Conkling of Moraga, ... Francisco, CA, has been elected Chair of the Board ... (AFB) -- the nearly 90-year-old organization to which Helen Keller ... in New York with offices in San Francisco, ... WV, AFB is dedicated to expanding possibilities for people ...
(Date:12/14/2009)... 14 Following is a statement of ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) ,, The 2009 ... National Institute of Drug Abuse shows that the ... youth smoking, but declines have slowed significantly compared ... In especially troubling news, the survey also ...
(Date:12/14/2009)... 2009 Only about one in 2,000 people in the ... one of the unfortunate few. , Ms. Wilcox,s tumor was ... even those problems were mistaken for blocked sinuses. , "For ... of my nose," recalled the resident of Goldthwaite, a town ... Country. "I felt a fullness, but I didn,t take that ...
Breaking Medicine News(10 mins):Health News:Looking Younger Than Your Age May Mean Longer Life 2Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 2Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 3Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 4Health News:The American Foundation for the Blind Welcomes New Board Chair, Concetta F. Conkling 2Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 2Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 3Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 4Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 5Health News:Minimally invasive surgery removes sinus tumor without facial disfiguration 2
... BiotelCONSHOHOCKEN, Pa., April 2 CardioNet, Inc. (Nasdaq: ... with an initial focus on the diagnosis and monitoring ... cardiac clinical research services business and the acquisition of ... companies entered into a binding definitive merger agreement for ...
... Even as people struggle to cope with economic uncertainty ... live a joyful, vital "best" life in these hard times. ... psychiatrist Dr. Richard Esser has helped people find their "best" ... Stockholm, Sweden, Esser discovered that when we learn how to ...
... Italy, 2 April 2009 - In a study conducted ... Caen Basse-Normandie and published by Elsevier in the April ... researchers studied for the first time autobiographical memory in ... disease progression. They highlighted that at early stages of ...
... Lenses to Be FeaturedSAN FRANCISCO, April 2 Over ... symposium at a San Francisco hotel Friday night. They ... Whitman broadcast live from Key Whitman Eye Center in ... only FDA approved accommodating Intraocular lens (IOL) in one ...
... Md, April 2 Solta Medical, Inc. (Nasdaq: ... physicians in skin tightening and resurfacing today from 6:00 ... of American Society for Lasers in Medicine & Surgery ... Michael Kaminer, Tina Alster, Amy Taub and Robert Weiss ...
... InVitria,s Recombinant Albumin-DX eliminates safety concerns, stabilizes sensitive biomarkers ... ... Fort Collins, CO ... and consistency issues in the human diagnostics market, InVitria ...
Other Medicine News:Health News:CardioNet Expands Product Offering and Launches Clinical Research Services 2Health News:CardioNet Expands Product Offering and Launches Clinical Research Services 3Health News:CardioNet Expands Product Offering and Launches Clinical Research Services 4Health News:CardioNet Expands Product Offering and Launches Clinical Research Services 5Health News:CardioNet Expands Product Offering and Launches Clinical Research Services 6Health News:Psychiatrist Dr. Richard Esser: How to Find the Best of Life in the Worst of Times 2Health News:Effects of disease severity on autobiographical memory in semantic dementia revealed in new study 2Health News:Surgeons to Observe and Discuss Live Eye Surgery Friday Night in San Francisco 2Health News:Surgeons to Observe and Discuss Live Eye Surgery Friday Night in San Francisco 3Health News:Solta Medical Presents Expert Roundtable about Thermage(R) and Fraxel(R) Combination Treatments at ASLMS Annual Meeting 2Health News:Solta Medical Presents Expert Roundtable about Thermage(R) and Fraxel(R) Combination Treatments at ASLMS Annual Meeting 3Health News:InVitria Announces Launch of Recombinant Albumin for Diagnostics 2
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
InterVascular HemaPatch product line offers the vascular surgeon a range of collagen coated patches in a range of larger sizes angioplasty, or profundaplasty procedures without suture hole bleeding. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
... The Chito-Seal Topical Hemostasis Pad is intended for ... as vascular access sites and percutaneous catheters or ... chitosan gel, a powerful hemostatic agent. Chitosan gel ... marine biopolymer from which it is derived. When ...
Medicine Products: